lomefloxacin has been researched along with Acute Disease in 16 studies
lomefloxacin: structure given in first source
lomefloxacin : A fluoroquinolone antibiotic, used (generally as the hydrochloride salt) to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "3% lomefloxacin single agent solution, by comparing to a combination of fortified ophthalmic solutions of cefazolin sodium 50 mg/ml and gentamicin sulfate 14 mg/ml, in the treatment of acute bacterial keratitis." | 9.11 | Clinical evaluation of ophthalmic lomefloxacin 0.3% in comparison with fortified cefazolin and gentamicin ophthalmic solutions in the treatment of presumed bacterial keratitis. ( Erjongmanee, S; Kasetsuwan, N; Pariyakanok, L; Phusitphoykai, N; Puangsricharern, V, 2004) |
| "The bacteriologic and clinical efficacies of 3 days of lomefloxacin therapy were compared with those of 3 days of norfloxacin therapy for the treatment of acute uncomplicated urinary tract infections in a prospective, randomized, double-blind study." | 9.07 | Treatment of acute uncomplicated urinary tract infections with 3 days of lomefloxacin compared with treatment with 3 days of norfloxacin. ( Conly, JM; DuBois, J; Harding, GK; Martel, AY; Nicolle, LE; Shafran, SD, 1993) |
| "Nine centers in Italy participated in a worldwide, multicenter study comparing the effectiveness and safety of lomefloxacin and amoxicillin in patients with acute exacerbations of chronic bronchitis caused mainly by gram-negative pathogens." | 9.07 | Lomefloxacin versus amoxicillin in the treatment of acute exacerbations of chronic bronchitis: an Italian multicenter study. ( Albera, C; Grassi, C; Pozzi, E, 1992) |
| "In two multicenter trials, lomefloxacin and cefaclor were compared as treatments for acute bacterial exacerbations of chronic bronchitis." | 9.07 | Safety and efficacy of lomefloxacin versus cefaclor in the treatment of acute exacerbations of chronic bronchitis. ( Ellison, WT; Gotfried, MH, 1992) |
| "The efficacy and safety of 7-10-day courses of lomefloxacin (single daily dose of 400 mg) or norfloxacin (twice-daily doses of 400 mg) for the treatment of uncomplicated urinary tract infections were compared in two large, multicenter, randomized trials." | 9.07 | Efficacy of lomefloxacin as compared to norfloxacin in the treatment of uncomplicated urinary tract infections in adults. ( Iravani, A, 1992) |
| "A total of 63 adult patients with uncomplicated acute pyelonephritis were enrolled in a multicenter, randomized comparison of lomefloxacin (400 mg orally once daily for 14 days) and trimethoprim/sulfamethoxazole (TMP/SMX, 160/800 mg orally twice daily for 14 days)." | 9.07 | A multicenter study of lomefloxacin and trimethoprim/sulfamethoxazole in the treatment of uncomplicated acute pyelonephritis. ( Ajana, F; Capron, MH; Chidiac, C; Home, P; Masquelier, AM; Mouton, Y, 1992) |
| "To objectively evaluate the efficacy, safety and utility of lomefloxacin (NY-198), a new quinolone antibacterial agent, in the treatment of acute uncomplicated cystitis, a comparative double blind trial was performed using norfloxacin (NFLX) as the control drug." | 9.06 | [A comparative study on lomefloxacin and norfloxacin in the treatment of acute uncomplicated cystitis]. ( Amano, M; Arakawa, S; Fujita, Y; Ishigami, J; Kamidono, S; Kanemasa, Y; Kumon, H; Ohmori, H; Suzuki, K; Tanaka, H, 1989) |
| "Lomefloxacin is a difluorinated quinolone with excellent activity against a wide range of pathogens including those responsible for acute exacerbations of chronic bronchitis (AECB)." | 7.71 | Safety and effectiveness of lomefloxacin in patients with acute exacerbation of chronic bronchitis (AECB) chronically treated with oral theophyllines. ( Cantoni, V; Melani, AS; Pirrelli, M; Sarlo, F, 2001) |
| " Although there were no statistically significant differences between the two LFLX dosage groups for these parameters at either of the evaluation times, the rates for the 300-mg LFLX dose were slightly superior." | 6.68 | [Clinical efficacy of lomefloxacin (100 mg or 300 mg) single-dose therapy in female acute uncomplicated cystitis]. ( Aoki, M; Hirose, T; Kumamoto, Y; Miyake, M; Sakai, S; Shibuya, A; Shimamura, S; Takatsuka, K; Umehara, T; Yamazaki, K, 1995) |
| "Lomefloxacin was the only antibiotic currently authorized for use in a three-day regimen for the treatment of lower urinary tract infections." | 6.68 | [Treatment of non-complicated acute cystitis in women: lomefloxacin versus pefloxacin]. ( Capron, MH; Giacomino, A; Guibert, J, 1996) |
| "3% lomefloxacin single agent solution, by comparing to a combination of fortified ophthalmic solutions of cefazolin sodium 50 mg/ml and gentamicin sulfate 14 mg/ml, in the treatment of acute bacterial keratitis." | 5.11 | Clinical evaluation of ophthalmic lomefloxacin 0.3% in comparison with fortified cefazolin and gentamicin ophthalmic solutions in the treatment of presumed bacterial keratitis. ( Erjongmanee, S; Kasetsuwan, N; Pariyakanok, L; Phusitphoykai, N; Puangsricharern, V, 2004) |
| "The bacteriologic and clinical efficacies of 3 days of lomefloxacin therapy were compared with those of 3 days of norfloxacin therapy for the treatment of acute uncomplicated urinary tract infections in a prospective, randomized, double-blind study." | 5.07 | Treatment of acute uncomplicated urinary tract infections with 3 days of lomefloxacin compared with treatment with 3 days of norfloxacin. ( Conly, JM; DuBois, J; Harding, GK; Martel, AY; Nicolle, LE; Shafran, SD, 1993) |
| "Nine centers in Italy participated in a worldwide, multicenter study comparing the effectiveness and safety of lomefloxacin and amoxicillin in patients with acute exacerbations of chronic bronchitis caused mainly by gram-negative pathogens." | 5.07 | Lomefloxacin versus amoxicillin in the treatment of acute exacerbations of chronic bronchitis: an Italian multicenter study. ( Albera, C; Grassi, C; Pozzi, E, 1992) |
| "In two multicenter trials, lomefloxacin and cefaclor were compared as treatments for acute bacterial exacerbations of chronic bronchitis." | 5.07 | Safety and efficacy of lomefloxacin versus cefaclor in the treatment of acute exacerbations of chronic bronchitis. ( Ellison, WT; Gotfried, MH, 1992) |
| "The efficacy and safety of 7-10-day courses of lomefloxacin (single daily dose of 400 mg) or norfloxacin (twice-daily doses of 400 mg) for the treatment of uncomplicated urinary tract infections were compared in two large, multicenter, randomized trials." | 5.07 | Efficacy of lomefloxacin as compared to norfloxacin in the treatment of uncomplicated urinary tract infections in adults. ( Iravani, A, 1992) |
| "A total of 63 adult patients with uncomplicated acute pyelonephritis were enrolled in a multicenter, randomized comparison of lomefloxacin (400 mg orally once daily for 14 days) and trimethoprim/sulfamethoxazole (TMP/SMX, 160/800 mg orally twice daily for 14 days)." | 5.07 | A multicenter study of lomefloxacin and trimethoprim/sulfamethoxazole in the treatment of uncomplicated acute pyelonephritis. ( Ajana, F; Capron, MH; Chidiac, C; Home, P; Masquelier, AM; Mouton, Y, 1992) |
| "To objectively evaluate the efficacy, safety and utility of lomefloxacin (NY-198), a new quinolone antibacterial agent, in the treatment of acute uncomplicated cystitis, a comparative double blind trial was performed using norfloxacin (NFLX) as the control drug." | 5.06 | [A comparative study on lomefloxacin and norfloxacin in the treatment of acute uncomplicated cystitis]. ( Amano, M; Arakawa, S; Fujita, Y; Ishigami, J; Kamidono, S; Kanemasa, Y; Kumon, H; Ohmori, H; Suzuki, K; Tanaka, H, 1989) |
| "Lomefloxacin is a difluorinated quinolone with excellent activity against a wide range of pathogens including those responsible for acute exacerbations of chronic bronchitis (AECB)." | 3.71 | Safety and effectiveness of lomefloxacin in patients with acute exacerbation of chronic bronchitis (AECB) chronically treated with oral theophyllines. ( Cantoni, V; Melani, AS; Pirrelli, M; Sarlo, F, 2001) |
| " Although there were no statistically significant differences between the two LFLX dosage groups for these parameters at either of the evaluation times, the rates for the 300-mg LFLX dose were slightly superior." | 2.68 | [Clinical efficacy of lomefloxacin (100 mg or 300 mg) single-dose therapy in female acute uncomplicated cystitis]. ( Aoki, M; Hirose, T; Kumamoto, Y; Miyake, M; Sakai, S; Shibuya, A; Shimamura, S; Takatsuka, K; Umehara, T; Yamazaki, K, 1995) |
| "Confirmation of recurrence was carried out to the greatest extent possible." | 2.68 | [Long-term monitoring of female acute uncomplicated cystitis cases after lomefloxacin single-dose therapy]. ( Aoki, M; Hirose, T; Kumamoto, Y; Miyake, M; Sakai, S; Shibuya, A; Shimamura, S; Takatsuka, K; Umehara, T; Yamazaki, K, 1995) |
| "Forty-five patients with presumed acute bacterial conjunctivitis were treated in an investigator-masked randomized multicenter study with either lomefloxacin 0." | 2.68 | Topical lomefloxacin twice daily compared with fucidic acid in acute bacterial conjunctivitis. ( Jauch, A; Kari, O; Latvala, ML; Malminiemi, K; Miettinen, A; Voutilainen, R, 1996) |
| "Lomefloxacin was the only antibiotic currently authorized for use in a three-day regimen for the treatment of lower urinary tract infections." | 2.68 | [Treatment of non-complicated acute cystitis in women: lomefloxacin versus pefloxacin]. ( Capron, MH; Giacomino, A; Guibert, J, 1996) |
| "Uncomplicated acute cystitis is one of the most common bacterial infections in adults." | 2.43 | Quinolones for uncomplicated acute cystitis in women. ( Andreeva, I; Rafalsky, V; Rjabkova, E, 2006) |
| "Lomefloxacin eye drops used with a loading dosage followed by a twice daily regimen proved as effective, safe and well tolerated as five established standard treatments used at a 2, 4 or 5 times daily regimen, caused less discomfort upon instillation, and showed a lower risk to generate or select new resistant strains." | 2.40 | Meta-analysis of six clinical phase III studies comparing lomefloxacin 0.3% eye drops twice daily to five standard antibiotics in patients with acute bacterial conjunctivitis. ( Fsadni, M; Gamba, G; Jauch, A, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 12 (75.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Erjongmanee, S | 1 |
| Kasetsuwan, N | 1 |
| Phusitphoykai, N | 1 |
| Puangsricharern, V | 1 |
| Pariyakanok, L | 1 |
| Rafalsky, V | 1 |
| Andreeva, I | 1 |
| Rjabkova, E | 1 |
| Hirose, T | 2 |
| Kumamoto, Y | 2 |
| Sakai, S | 2 |
| Shimamura, S | 2 |
| Shibuya, A | 2 |
| Yamazaki, K | 2 |
| Umehara, T | 2 |
| Miyake, M | 2 |
| Takatsuka, K | 2 |
| Aoki, M | 2 |
| Nicolle, LE | 1 |
| DuBois, J | 1 |
| Martel, AY | 1 |
| Harding, GK | 1 |
| Shafran, SD | 1 |
| Conly, JM | 1 |
| Malminiemi, K | 1 |
| Kari, O | 1 |
| Latvala, ML | 1 |
| Voutilainen, R | 1 |
| Miettinen, A | 1 |
| Jauch, A | 3 |
| Guibert, J | 1 |
| Capron, MH | 2 |
| Giacomino, A | 1 |
| Sokolova, GB | 1 |
| Kunichan, AD | 1 |
| Koriakin, VA | 1 |
| Lazareva, IaV | 1 |
| Gallenga, PE | 1 |
| Lobefalo, L | 1 |
| Colangelo, L | 1 |
| Della Loggia, G | 1 |
| Orzalesi, N | 1 |
| Velati, P | 1 |
| Bujtar, E | 1 |
| Ponte, F | 1 |
| Damiani, S | 1 |
| Bucci, MG | 1 |
| Bonini, S | 1 |
| Curatola, MR | 1 |
| Palma, LA | 1 |
| Bonomi, L | 1 |
| Tomazzoli Gerosa, L | 1 |
| Pagliarusco, A | 1 |
| Milan, E | 1 |
| Fsadni, M | 1 |
| Gamba, G | 1 |
| Melani, AS | 1 |
| Pirrelli, M | 1 |
| Sarlo, F | 1 |
| Cantoni, V | 1 |
| Grassi, C | 1 |
| Albera, C | 1 |
| Pozzi, E | 1 |
| Gotfried, MH | 1 |
| Ellison, WT | 1 |
| Iravani, A | 1 |
| Mouton, Y | 1 |
| Ajana, F | 1 |
| Chidiac, C | 1 |
| Home, P | 1 |
| Masquelier, AM | 1 |
| Ohmori, H | 1 |
| Kumon, H | 1 |
| Suzuki, K | 1 |
| Kamidono, S | 1 |
| Arakawa, S | 1 |
| Ishigami, J | 1 |
| Tanaka, H | 1 |
| Amano, M | 1 |
| Fujita, Y | 1 |
| Kanemasa, Y | 1 |
2 reviews available for lomefloxacin and Acute Disease
| Article | Year |
|---|---|
Quinolones for uncomplicated acute cystitis in women.
Topics: Acute Disease; Adult; Anti-Infective Agents, Urinary; Ciprofloxacin; Cystitis; Female; Fluoroquinolo | 2006 |
Meta-analysis of six clinical phase III studies comparing lomefloxacin 0.3% eye drops twice daily to five standard antibiotics in patients with acute bacterial conjunctivitis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Infective Agents; Child; Clinical Trials, Phase III as | 1999 |
13 trials available for lomefloxacin and Acute Disease
| Article | Year |
|---|---|
Clinical evaluation of ophthalmic lomefloxacin 0.3% in comparison with fortified cefazolin and gentamicin ophthalmic solutions in the treatment of presumed bacterial keratitis.
Topics: Acute Disease; Adolescent; Adult; Anti-Bacterial Agents; Cefazolin; Double-Blind Method; Female; Flu | 2004 |
[Clinical efficacy of lomefloxacin (100 mg or 300 mg) single-dose therapy in female acute uncomplicated cystitis].
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Anti-Infective Agents; Cystitis; Doubl | 1995 |
[Long-term monitoring of female acute uncomplicated cystitis cases after lomefloxacin single-dose therapy].
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Anti-Infective Agents; Double-Blind Me | 1995 |
Treatment of acute uncomplicated urinary tract infections with 3 days of lomefloxacin compared with treatment with 3 days of norfloxacin.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Infective Agents; Canada; Double-Blind Method; Female; | 1993 |
Topical lomefloxacin twice daily compared with fucidic acid in acute bacterial conjunctivitis.
Topics: Acute Disease; Administration, Topical; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Colo | 1996 |
[Treatment of non-complicated acute cystitis in women: lomefloxacin versus pefloxacin].
Topics: Acute Disease; Adult; Anti-Infective Agents; Cystitis; Family Practice; Female; Fluoroquinolones; Hu | 1996 |
[Lomefloxacin in complex treatment of acute progressive form of pulmonary tuberculosis].
Topics: Acute Disease; Adolescent; Adult; Animals; Anti-Infective Agents; Antibiotics, Antitubercular; Antit | 1998 |
Topical lomefloxacin 0.3% twice daily versus tobramycin 0.3% in acute bacterial conjunctivitis: A multicenter double-blind phase III study.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Age | 1999 |
Lomefloxacin versus amoxicillin in the treatment of acute exacerbations of chronic bronchitis: an Italian multicenter study.
Topics: Acute Disease; Aged; Amoxicillin; Anti-Infective Agents; Bronchitis; Chi-Square Distribution; Chroni | 1992 |
Safety and efficacy of lomefloxacin versus cefaclor in the treatment of acute exacerbations of chronic bronchitis.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Cefaclor; Chronic | 1992 |
Efficacy of lomefloxacin as compared to norfloxacin in the treatment of uncomplicated urinary tract infections in adults.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Drug Administratio | 1992 |
A multicenter study of lomefloxacin and trimethoprim/sulfamethoxazole in the treatment of uncomplicated acute pyelonephritis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Escherichia coli I | 1992 |
[A comparative study on lomefloxacin and norfloxacin in the treatment of acute uncomplicated cystitis].
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Infective Agents; Bacteria; Child; Clinical Trials as T | 1989 |
1 other study available for lomefloxacin and Acute Disease
| Article | Year |
|---|---|
Safety and effectiveness of lomefloxacin in patients with acute exacerbation of chronic bronchitis (AECB) chronically treated with oral theophyllines.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Infective Agents; Bronchitis; Cross-Sectional | 2001 |